Paul Edward Gross Form 3 Clovis Oncology / Paul Edward Gross ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Gross Paul Edward

(Last) (First) (Middle)

C/O CLOVIS ONCOLOGY, INC.

5500 FLATIRON PARKWAY, SUITE 100

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/01/2019

3. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,345	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	01/25/2026	Common Stock	60,000	22.99	D
Stock Option (right to buy)	(2)	03/27/2027	Common Stock	15,000	68.31	D
Stock Option (right to buy)	(3)	03/01/2028	Common Stock	9,000	58.43	D
Restricted Stock Units	(4)	03/27/2027	Common Stock	4,219	(5)	D
Restricted Stock Units	(6)	03/01/2028	Common Stock	9,000	(5)	D

Explanation of Responses:

1. The option vested as to 25% of the shares on January 25, 2017, and the remainder vests in substantially equal installments over the 36 months immediately following such date.

2. The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date.

3. The option vests as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date.

4. The Restricted Stock Units vested as to 25% of the units on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

5. Each Restricted Stock Unit represents the right to receive one share of Common Stock.

6. The Restricted Stock Units vest as to 25% of the units on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Executive Vice President, General Counsel and Chief Compliance Officer

	/s/ Paul Gross	02/01/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.